| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Bill outlines FDA ‘progressive’ and ‘exceptional’ drug approval pathways
|
Gingery, Derrick
|
|
2011
|
8 |
11 |
p. 528-
1 p.
|
article
|
| 2 |
Bisphosphonates reduce risk of breast cancer metastases
|
Jancin, Bruce
|
|
2011
|
8 |
11 |
p. 525-526
2 p.
|
article
|
| 3 |
Current therapies seen as having multiple myeloma ‘on the ropes’
|
|
|
2011
|
8 |
11 |
p. 522-523
2 p.
|
article
|
| 4 |
Everolimus overcomes hormonal resistance in ER-positive breast cancer
|
Abraham, Jame
|
|
2011
|
8 |
11 |
p. 497-498
2 p.
|
article
|
| 5 |
FDA adds fertility, osteonecrosis, VTE risks to bevacizumab label
|
Mechcatie, Elizabeth
|
|
2011
|
8 |
11 |
p. 524-
1 p.
|
article
|
| 6 |
Increased PAH risk seen with dasatinib
|
Mechcatie, Elizabeth
|
|
2011
|
8 |
11 |
p. 524-525
2 p.
|
article
|
| 7 |
Lymphedema common after head and neck cancer therapy
|
|
|
2011
|
8 |
11 |
p. 521-522
2 p.
|
article
|
| 8 |
Patient-centered care and distress screening: tracking the sixth vital sign
|
Schwartzberg, Lee S.
|
|
2011
|
8 |
11 |
p. 491-
1 p.
|
article
|
| 9 |
Political battles brew over breast density
|
Schneider, Mary Ellen
|
|
2011
|
8 |
11 |
p. 526-527
2 p.
|
article
|
| 10 |
Refined risk stratification guides leukemia transplant decisions
|
LONDON, SUSAN
|
|
2011
|
8 |
11 |
p. 520-521
2 p.
|
article
|
| 11 |
Screening cancer patients for distress: guidelines for routine implementation
|
Lowery, Amy E.
|
|
2011
|
8 |
11 |
p. 502-505
4 p.
|
article
|
| 12 |
The beginning of small molecule therapy for endocrine-resistant metastatic breast cancer?
|
Brufsky, Adam
|
|
2011
|
8 |
11 |
p. 498-500
3 p.
|
article
|
| 13 |
The impact of bone metastases and skeletal-related events on healthcare costs in prostate cancer patients receiving hormonal therapy
|
Hagiwara, May
|
|
2011
|
8 |
11 |
p. 508-515
8 p.
|
article
|
Journal description